Skip to content
naulon

Not checkedNot checked for notices yet.

DTI-015 Produces Cures in T9 Gliosarcoma

Dennis Pietronigro, Frank Dmovsky, Humberto Cravioto and 1 more

Neoplasia: An International Journal for Oncology Research · 2003

doi:10.1016/s1476-5586(03)80013-1 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

DTI-015 (BCNU in 100% ethanol) utilizes solventfacilitated perfusion for the intratumoral treatment of gliomas. The water-miscible organic solvent vehicle, ethanol, facilitates a rapid and thorough saturation of the tumor with the dissolved anticancer agent, BCNU. Rats bearing established intracranial T9 gliosarcoma tumors received no treatment (group 1), a single intratumoral injection of ethanol vehicle (group 2) or DTI-015 (5 mg/kg BCNU) (group 3), or a single intratumoral injection of DTI-015 followed by systemic BCNU (group 4). Ethanol alone (n=13) had no effect on survival; MST = 17 days compared to 18 days for untreated controls (n=35). DTI-015 (n=45) produced an I LS of 417% (MST = 93) and 472% (MST = 103) when combined with systemic BCNU (n=14). Overall, 24 of 59 rats receiving DTI-015 were judged to be cured, with 20 living a normal life span of 600 to 700 days, and 4 rats sacrificed healthy at 121, 135, 307, and 384 days post DTI-015 with no evidence of viable T9 tumor. Histology demonstrated that DTI-015 totally eradicated the T9 tumors in animals living a normal life span. The results demonstrate that a single injection of DTI-015 produces a 40% cure rate in rats bearing established intracranial T9 tumors.

Abstract licence: CC BY-NC

References28

    28 more references, whose wording the paper’s licence keeps private.

    Reads

    Read by people on this page

    None yet.

    Checked or read by AI through naulon

    None yet.

    A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

    Are you an author?

    Is this your paper?

    Claim it to add your note and be paid when agents cite it. Free.